Fabrication of rosuvastatin-loaded polymeric nanocapsules: A promising modality for treating hepatic cancer delineated by apoptotic and cell cycle arrest assessment.

Fabrication of rosuvastatin-loaded polymeric nanocapsules: A promising modality for treating hepatic cancer delineated by apoptotic and cell cycle arrest assessment. Drug Dev Ind Pharm. 2018 Aug 24;:1-29 Authors: Aldalaen S, El-Gogary RI, Nasr M Abstract Nanotechnology has provided several advantages for the treatment of cancer. Polymeric nanocapsules (PNCs) were proven promising in the treatment of different cancer types, such as hepatic cancer. Meanwhile, the exploration of novel indications of old molecules with the purpose of cancer treatment has been widely reported. Among the promising therapeutic moieties, rosuvastatin (RV) was delineated as a potential anticancer drug. Hence, the target of the presented manuscript was to develop PNCs loaded with RV to overcome its delivery challenges and augment its anticancer activity. RV PNCs were fabricated by the nanoprecipitation method using poly-lactide-co-glycolide PLGA polymer, and were characterized for the size, polydispersity index (PDI), charge, entrapment efficiency EE%, in-vitro release, stability, and morphology. Furthermore, their anticancer activity was tested on HepG2 cells using MTT assay, followed by elucidating the cytotoxic activity using flow cytometry. Results showed that RV PNCs displayed particle size ranging from 186-239 nm, average PDI, and negative zeta potential with sufficient stability for 3 months. PNCs were able to load RV at high EE% reaching 82.6% and su...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research